Neurodegenerative diseases, in particular the dementia’s like Alzheimer’s disease, have no known therapy treating the root cause of the disease. ProMIS’s focus is to use our unique proprietary technology to identify and develop antibody therapies targeting neurodegenerative diseases. ProMIS will continue to demonstrate the potential for a lead program to be best-in-class therapy for Alzheimer’s disease. We look forward to initiating clinical trials in 2019.
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF). As a development stage biotech company, ProMIS’ mission is to discover and develop best in class precision therapeutics for treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
ProMIS Neurosciences utilizes two proprietary computational discovery technologies, ProMIS™ and Collective Coordinates, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS Neurosciences has a robust patent estate relating to misfolded SOD1 in ALS and multiple patents for disease specific epitopes (targets) and monoclonal antibodies (mAbs) selectively targeting toxic misfolded Amyloid beta oligomers (AβO) in AD.
For more information on ProMIS Neurosciences Inc. (PMN:TSX, ARFXF:OTCQB) please fill out the form below.